Literature DB >> 16470079

Management strategies for patients with hypertension and diabetes: why combination therapy is critical.

Sara Giunti1, Mark Cooper.   

Abstract

Hypertension is commonly associated and acts synergistically with diabetes in increasing the risk of macrovascular and microvascular diabetic complications. Large-scale clinical trials have demonstrated that this risk is significantly reduced by intensive antihypertensive treatment, and accordingly, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guideline has further lowered the blood pressure goals for diabetic subjects to <130/80 mm Hg. This implies that most diabetic patients will require the combination of two or more antihypertensive agents to achieve this blood pressure target. Although the most effective combination strategy in diabetes has not yet been determined in large-scale randomized clinical trials, a combination that includes at least one agent that interrupts the renin-angiotensin system appears to not only have a good safety profile, but may also provide additional renal and cardiovascular protection. Other antihypertensive agents should be added based on the patients risk profile and overall treatment regimen to achieve blood pressure goal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470079      PMCID: PMC8109387          DOI: 10.1111/j.1524-6175.2005.04508.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  40 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

3.  Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes.

Authors:  M Schneider; M Lerch; M Papiri; P Buechel; L Boehlen; S Shaw; W Risen; P Weidmann
Journal:  J Hypertens       Date:  1996-05       Impact factor: 4.844

4.  Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J Tuomilehto; D Rastenyte; W H Birkenhäger; L Thijs; R Antikainen; C J Bulpitt; A E Fletcher; F Forette; A Goldhaber; P Palatini; C Sarti; R Fagard
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

5.  Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Birgitte V Hansen; Hans-Henrik Parving
Journal:  Nephrol Dial Transplant       Date:  2002-06       Impact factor: 5.992

6.  Influence of diabetes and type of hypertension on response to antihypertensive treatment.

Authors:  M J Brown; A Castaigne; P W de Leeuw; G Mancia; C R Palmer; T Rosenthal; L M Ruilope
Journal:  Hypertension       Date:  2000-05       Impact factor: 10.190

7.  Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Berit R Jensen; Hans-Henrik Parving
Journal:  J Am Soc Nephrol       Date:  2003-04       Impact factor: 10.121

8.  Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

Authors:  Niels H Andersen; Per L Poulsen; Søren T Knudsen; Steen H Poulsen; Hans Eiskjaer; Klavs W Hansen; Kjeld Helleberg; Carl E Mogensen
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

9.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

10.  The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.

Authors:  Jonathan C Fox; Kellie Leight; Santosh C Sutradhar; Laura A Demopoulos; Gilbert W Gleim; Andrew J Lewin; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-08       Impact factor: 3.738

View more
  8 in total

1.  Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics.

Authors:  Adam de Havenon; Jennifer J Majersik; David L Tirschwell; J Scott McNally; Gregory Stoddard; Natalia S Rost
Journal:  Neurology       Date:  2019-02-08       Impact factor: 9.910

2.  Patterns and associated health services costs of antihypertensive drug modifications.

Authors:  Shadi S Saleh; Steven Szebenyi; Judith A Carter; Chris Zacher; Dan Belletti
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

3.  Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors.

Authors:  Alberto F Rubio-Guerra; David Castro-Serna; Cesar I Elizalde Barrera; Luz M Ramos-Brizuela
Journal:  Integr Blood Press Control       Date:  2009-11-23

4.  Aggressive blood pressure-lowering therapy guided by home blood pressure monitoring improves target organ damage in hypertensive patients with type 2 diabetes/prediabetes.

Authors:  Kazuo Eguchi; Satoshi Hoshide; Shizukiyo Ishikawa; Kazuyuki Shimada; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-18       Impact factor: 3.738

Review 5.  Emerging insights in the first-step use of antihypertensive combination therapy.

Authors:  Keith Norris; Joel M Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-12       Impact factor: 3.738

6.  Initial combination therapy compared with monotherapy in diabetic hypertensive patients.

Authors:  James R Sowers; Guido Lastra; Ricardo Rocha; Yodit Seifu; Nora Crikelair; Drew G Levy
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-09       Impact factor: 3.738

7.  Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats.

Authors:  Qiaoling Zhou; Kanghan Liu; Hongyu Wu; Lihe Chen; Veeraragoo Pouranan; Mingxia Yuan; Zhou Xiao; Weisheng Peng; Ao Xiang; Rong Tang; Wenzheng Zhang
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

Review 8.  Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk.

Authors:  H Haller
Journal:  Int J Clin Pract       Date:  2008-03-17       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.